TIGRIS血管支架在现代治疗算法中的前瞻性评估
这项前瞻性单中心研究纳入97例患者共100处股腘动脉病变,仅在球囊预扩张后出现回缩或夹层时置入TIGRIS支架。12个月主要通畅率为92.9%,免于靶病变血运重建率为94.9%,24个月Kaplan-Meier主要通畅率估计为90.0%,未发生器械相关并发症。
要点
- TIGRIS支架在股浅动脉和近端腘动脉病变中12个月主要通畅率达92.9%。
- 支架仅用于球囊预扩张后回缩或夹层的现代治疗算法下,器械相关并发症为零。
- 24个月Kaplan-Meier主要通畅率估计为90.0%,免于TLR为94.9%。
核心结论
- 在现代治疗算法中,将裸支架保留用于膝下股腘动脉球囊扩张后夹层或回缩,TIGRIS血管支架安全有效。
研究设计与样本
- 前瞻性单中心研究纳入97例患者(平均年龄68.7岁,66例男性),治疗100处新发或非支架内再狭窄的股腘动脉病变(狭窄≥70%),病变平均长度5.6±2.3 cm。
主要发现
- 12个月二分类主要通畅率和次要通畅率分别为92.9%和100%,免于TLR为94.9%。
- 24个月Kaplan-Meier主要通畅率估计为90.0%。
- 所有器械成功置入,置入时及30天内无器械相关并发症,支架释放中未观察到支架伸长。
关键数值与推荐
- 主要疗效终点为12个月主要通畅,定义为支架段靶病变收缩期峰值流速比≤2.5且无临床驱动的支架段内再干预。
- 主要安全终点为30天内免于器械或手术相关的靶血管血运重建、靶肢体大截肢(跖骨以上)或死亡。
临床怎么用
- 对于股腘动脉病变,可先进行普通球囊预扩张,仅在出现回缩或夹层时置入TIGRIS支架。
局限性
- 单中心前瞻性研究,样本量有限,24个月分析仅77例患者/病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To prospectively evaluate the safety and efficacy of the TIGRIS Vascular Stent in the superficial femoral artery (SFA) and proximal popliteal artery within a treatment algorithm that reserved stent usage for more challenging patients. Materials and Methods: This prospective, single-center study enrolled 97 patients (mean age 68.7 years; 66 men) who were treated for 100 de novo or nonstented restenotic femoropopliteal lesions (≥70% stenosis) and had recoil or dissection after plain balloon predilation. The average lesion length was 5.6±2.3 cm (maximum 8 cm per protocol). The composite primary efficacy outcome was 12-month primary patency, defined as a peak systolic velocity ratio ≤2.5 at the stented target lesion on duplex ultrasound, and no clinically-driven reintervention within the stented segment. The primary safety outcome was freedom from device- and procedure-related target vessel revascularization, target limb major amputation (above the metatarsals), or death through 30 days. Secondary outcomes included secondary patency, clinically-driven target lesion revascularization (TLR), Rutherford category change relative to baseline, and binary restenosis of the target lesion. Results: All devices were successfully implanted with no device-related complications at the time of implant or within the 30-day postimplant window. The average stented length was 7.0±2.5 cm; no stent elongation was observed during deployment. One patient was lost to follow-up before 12 months and another died of an unrelated cause, leaving 95 patients (98 lesions) available for 12-month follow-up and 77 patients/lesions for the 24-month preliminary analysis. The binary primary and secondary patency rates at 12 months were 92.9% and 100%. The binary freedom from TLR was 94.9%. At 24 months, the Kaplan-Meier estimate of primary patency was 90.0%. Conclusion: This prospective study demonstrated that the TIGRIS Vascular Stent is a safe and effective device in a modern treatment algorithm that reserved bare stent use for postangioplasty dissection or recoil in distal femoropopliteal arteries.
引用
- Werner M, Gomari-Grisar F, Belalcazar S, et al. Prospective Evaluation of the TIGRIS Vascular Stent Within a Modern Treatment Algorithm. J Endovasc Ther. 2019. PMID: 31303096. doi:10.1177/1526602819862778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。